Journal article
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Abstract
BACKGROUND: Cardiovascular morbidity and mortality are higher among patients with type 2 diabetes, particularly those with concomitant cardiovascular diseases, than in most other populations. We assessed the effects of lixisenatide, a glucagon-like peptide 1-receptor agonist, on cardiovascular outcomes in patients with type 2 diabetes who had had a recent acute coronary event.
METHODS: We randomly assigned patients with type 2 diabetes who had …
Authors
Pfeffer MA; Claggett B; Diaz R; Dickstein K; Gerstein HC; Køber LV; Lawson FC; Ping L; Wei X; Lewis EF
Journal
New England Journal of Medicine, Vol. 373, No. 23, pp. 2247–2257
Publisher
Massachusetts Medical Society
Publication Date
December 3, 2015
DOI
10.1056/nejmoa1509225
ISSN
0028-4793